In this issue:
Mechanisms of resistance to noncovalent BTK inhibitors
Second-line tisagenlecleucel in aggressive B-cell lymphoma
Second-line axicabtagene ciloleucel in large B-cell lymphoma
Response-adapted postinduction strategy in follicular lymphoma
5-year results of brentuximab vedotin for CD30-positive PTCL
Second primary malignancies in MALT lymphomas
Uproleselan in R/R AML
Safety of zanubrutinib in B-cell malignancies
First-line ibrutinib in CLL with TP53 aberrations
Venetoclax + azacitidine and alloHCT in newly diagnosed AML
Please login below to download this issue (PDF)